Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. more
Time Frame | NVS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.27% | -2.12% | -2.22% |
1-Month Return | -5.8% | -3.42% | 0.07% |
3-Month Return | -16.24% | -11.13% | 3.71% |
6-Month Return | -8.16% | -5.74% | 8.04% |
1-Year Return | -0.03% | 3.97% | 26.32% |
3-Year Return | 20.24% | 1.05% | 29.42% |
5-Year Return | 8.84% | 34.37% | 83.36% |
10-Year Return | 21.79% | 97.88% | 185.56% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 48.68B | 49.90B | 52.88B | 51.83B | 46.66B | [{"date":"2019-12-31","value":92.06,"profit":true},{"date":"2020-12-31","value":94.37,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.02,"profit":true},{"date":"2023-12-31","value":88.24,"profit":true}] |
Cost of Revenue | 14.43B | 15.12B | 15.87B | 15.49B | 12.47B | [{"date":"2019-12-31","value":90.91,"profit":true},{"date":"2020-12-31","value":95.3,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.6,"profit":true},{"date":"2023-12-31","value":78.6,"profit":true}] |
Gross Profit | 34.25B | 34.78B | 37.01B | 36.34B | 34.19B | [{"date":"2019-12-31","value":92.55,"profit":true},{"date":"2020-12-31","value":93.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.2,"profit":true},{"date":"2023-12-31","value":92.38,"profit":true}] |
Gross Margin | 70.37% | 69.70% | 69.99% | 70.12% | 73.27% | [{"date":"2019-12-31","value":96.04,"profit":true},{"date":"2020-12-31","value":95.12,"profit":true},{"date":"2021-12-31","value":95.53,"profit":true},{"date":"2022-12-31","value":95.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 25.17B | 24.63B | 25.32B | 27.14B | 24.42B | [{"date":"2019-12-31","value":92.71,"profit":true},{"date":"2020-12-31","value":90.72,"profit":true},{"date":"2021-12-31","value":93.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.96,"profit":true}] |
Operating Income | 9.09B | 10.15B | 26.95B | 9.20B | 9.77B | [{"date":"2019-12-31","value":33.72,"profit":true},{"date":"2020-12-31","value":37.67,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":34.13,"profit":true},{"date":"2023-12-31","value":36.25,"profit":true}] |
Total Non-Operating Income/Expense | (791.00M) | (1.22B) | (17.04B) | (208.00M) | (1.14B) | [{"date":"2019-12-31","value":-79100000000,"profit":false},{"date":"2020-12-31","value":-122100000000,"profit":false},{"date":"2021-12-31","value":-1704100000000,"profit":false},{"date":"2022-12-31","value":-20800000000,"profit":false},{"date":"2023-12-31","value":-113800000000,"profit":false}] |
Pre-Tax Income | 8.94B | 9.88B | 26.14B | 8.37B | 9.12B | [{"date":"2019-12-31","value":34.2,"profit":true},{"date":"2020-12-31","value":37.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":32.03,"profit":true},{"date":"2023-12-31","value":34.9,"profit":true}] |
Income Taxes | 1.79B | 1.81B | 2.12B | 1.42B | 551.00M | [{"date":"2019-12-31","value":84.62,"profit":true},{"date":"2020-12-31","value":85.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.82,"profit":true},{"date":"2023-12-31","value":26,"profit":true}] |
Income After Taxes | 7.15B | 8.07B | 24.02B | 6.96B | 8.57B | [{"date":"2019-12-31","value":29.76,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.96,"profit":true},{"date":"2023-12-31","value":35.69,"profit":true}] |
Income From Continuous Operations | 7.15B | 8.07B | 24.02B | 6.96B | 8.15B | [{"date":"2019-12-31","value":29.76,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.96,"profit":true},{"date":"2023-12-31","value":33.95,"profit":true}] |
Income From Discontinued Operations | 4.59B | - | - | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 7.15B | 8.07B | 24.02B | 6.96B | 14.85B | [{"date":"2019-12-31","value":29.75,"profit":true},{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.95,"profit":true},{"date":"2023-12-31","value":61.82,"profit":true}] |
EPS (Diluted) | 5.28 | 5.78 | 6.29 | 6.12 | 6.90 | [{"date":"2019-12-31","value":76.52,"profit":true},{"date":"2020-12-31","value":83.77,"profit":true},{"date":"2021-12-31","value":91.16,"profit":true},{"date":"2022-12-31","value":88.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
NVS | |
---|---|
Cash Ratio | 0.50 |
Current Ratio | 1.11 |
Quick Ratio | 0.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NVS | |
---|---|
ROA (LTM) | 10.59% |
ROE (LTM) | 28.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NVS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.58 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.42 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NVS | |
---|---|
Trailing PE | 16.89 |
Forward PE | 11.82 |
P/S (TTM) | 3.87 |
P/B | 4.47 |
Price/FCF | 35 |
EV/R | 4.27 |
EV/Ebitda | 10.81 |
PEG | 2.88 |
Novartis AG ADR (NVS) share price today is $98.075
Yes, Indians can buy shares of Novartis AG ADR (NVS) on Vested. To buy Novartis AG ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Novartis AG ADR (NVS) via the Vested app. You can start investing in Novartis AG ADR (NVS) with a minimum investment of $1.
You can invest in shares of Novartis AG ADR (NVS) via Vested in three simple steps:
The 52-week high price of Novartis AG ADR (NVS) is $120.92. The 52-week low price of Novartis AG ADR (NVS) is $92.35.
The price-to-earnings (P/E) ratio of Novartis AG ADR (NVS) is 16.8883
The price-to-book (P/B) ratio of Novartis AG ADR (NVS) is 4.47
The dividend yield of Novartis AG ADR (NVS) is 3.86%
The market capitalization of Novartis AG ADR (NVS) is $193.47B
The stock symbol (or ticker) of Novartis AG ADR is NVS